Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 6/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891894 | 0.81 | PIK3CD (0.41) | PIK3CDCTSDCTSLCTSBCTSS | |
| SCHEMBL13340606 | 0.80 | MAPT (0.44) | CTSLCTSSSMN1; SMN2 | |
| SCHEMBL13207042 | 0.80 | PIK3CD (0.40) | PIK3CDCTSDCTSLCTSBCTSS | |
| SCHEMBL2585142 | 0.79 | PIK3CD (0.42) | PIK3CDCTSDCTSLCTSBCTSS | |
| SCHEMBL18928463 | 0.79 | PIK3CD (0.44) | PIK3CDCTSDCTSLCTSBCTSS | |
| SCHEMBL4973584 | 0.77 | PIK3CD (0.43) | PIK3CDCTSDCTSLCTSBCTSS | |
| SCHEMBL12524368 | 0.77 | EPHX1 (0.40) | PIK3CDCTSDCTSLCTSBCTSS | |
| SCHEMBL16912772 | 0.76 | PIK3CD (0.39) | PIK3CDSMN1; SMN2 | |
| SCHEMBL21816632 | 0.76 | CA14 (0.36) | CA14EPHX1 | |
| SCHEMBL13055387 | 0.76 | EPHX1 (0.53) | CA14CTSSMAOAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | PIK3CD 4403/4885CA14 3155/4885CTSD 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.